Biggest News Aggregation in the World
📰 Pals News

Page 94 - Pals News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Pals. Real-time updates on events, politics, business and more.

US FDA flexibility the question as Nurown goes before adcom

How flexible should the U.S. FDA evidentiary standards be for a therapy addressing a significant unmet need in a disease such as amyotrophic lateral sclerosis (ALS)? That’s the question the agency’s Cellular, Tissue and Gene Therapies Advisory Committee will ponder Sept. 27 as it looks at the data for Brainstorm Cell Therapuetics Inc.’s Nurown (debamestrocel), a mesenchymal stromal cell therapy targeting ALS.
Brainstorm Cell Therapuetics Inc Gene Therapies Advisory Committee Brainstorm Cell Therapuetics Amyotrophic Lateral Sclerosis Brainstorm Cell Therapeutics Inc Biogen Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Acurastem, Takeda strike $580M licensing deal for ALS, neurodegenerative drugs

Acurastem Inc. said on Sept. 25 that it struck an out-licensing deal potentially worth $580 million with Takeda Pharmaceutical Co. Ltd. to develop drugs for amyotrophic lateral sclerosis (ALS) and other PIKfyve gene-targeting therapeutics. Under the terms, Tokyo-headquartered Takeda obtains exclusive worldwide rights to Acurastem’s PIKfyve-targeting therapeutics, including Acurastem’s lead AS-202 asset, an antisense oligonucleotide therapy to treat ALS.
Acurastem Inc Takeda Pharmaceutical Co Takeda Pharmaceutical Tokyo Headquartered Takeda Acurastem Inc Takeda Pharmaceutical Co Ltd

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science